Join
Live feed
·
PRReleasevia Quantisnow
ProQR Therapeutics N.V. logo

ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10

ByQuantisnow·Wall Street's wire, on your screen.
PRQR· ProQR Therapeutics N.V.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PRQR (ProQR Therapeutics N.V.) and more on Quantisnow.